Revenue for the 2014/15 financial year was up by 7% to DKK 13,909 million, with the EBIT margin before special items at 33%. EBIT before special items increased by 9% to DKK 4,535 million.
“We’ve closed a difficult and challenging year with a good Q4 performance and, overall, satisfactory full-year results. The 7% organic growth we delivered is consistent with the revised guidance we announced earlier in the year,” said Coloplast CEO Lars Rasmussen.
Sales growth by business area was as follows: Ostomy Care 6%, Continence Care 8%, Urology Care 5% and Wound & Skin Care 9%. Revenue increased by 5% in Europe, by 6% in other established markets and by 21% in Emerging markets.
Positive aspects in a difficult year “During the course of the year, we’ve encountered challenges in our two largest markets, the UK and the USA, that led to several guidance downgrades. Obviously, that is unsatisfactory, but it’s reassuring to know that we still have solid underlying momentum in our business, and I’m very optimistic about the upcoming financial year,” said Mr Rasmussen.
“One of the positive aspects of our full-year financial performance is our Wound & Skin Care business, which grew by 9%. We’ve also had outstanding product launches across the business, including the SenSura® Mio Convex ostomy bag and the SpeediCath® Compact Eve catheter,” said Mr Rasmussen.
For the 2015/2016 financial year, Coloplast projects revenue growth of 7-8% at constant exchange rates and of 8-9% in DKK, and an EBIT margin of 33-34%, both at constant exchange rates and in DKK.
Click here to read the full-year earnings release.
The Coloplast Annual Report for 2014/15 will be released later today. For more information, go to http://www.coloplast.com/Investor-Relations/Annual-reports/
Also later today, Coloplast will release its Corporate Responsibility Report for 2014/15. For more information, go to http://www.coloplast.com/About-Coloplast/Resp.../Policies/
PRESS CONTACT Simon Mehl Augustesen Senior Manager, Media Relations +45 4911 3488 dksia@coloplast.com
Dennis Kaysen Director, Corporate Communications +45 4911 2608 dkdk@coloplast.com
Financial highlights and key ratios 2014/15
| Financial highlights and key ratios (DKKm) | 2014/15 12M | 2013/14 12M | Change |
| Revenue | 13,909 | 12,428 | 12% |
| EBIT | 1,535 | 3,147 | (51%) |
| EBIT margin | 11% | 25% | (14%) p.p. |
| Special items | 3,000 | 1,000 | - |
| EBIT before special items | 4,535 | 4,147 | 9% |
| EBIT margin before special items | 33% | 33% | - |
| Sales performance by business area | DKKm 2014/15 12M | DKKm 2013/14 12M | Organic growth | Reported growth |
| Ostomy Care | 5,567 | 5,091 | 6% | 9% |
| Continence Care | 5,019 | 4,438 | 8% | 13% |
| Urology Care | 1,359 | 1,199 | 5% | 13% |
| Wound & Skin Care | 1,964 | 1,700 | 9% | 16% |
| Revenue | 13,909 | 12,428 | 7% | 12% |
Financial guidance for 2015/16
| Guidance 2015/16 | Guidance 2015/16 (DKK) | |
| Sales growth | 7-8% (organic) | 8-9% |
| EBIT margin | 33-34% (fixed) | 33-34% |
| CAPEX (DKKm) | - | ~700 |
| Tax rate | - | ~23% |
